Direct beneficial effects of GLP-1 agonism on retinal vasculature have also previously been reported in animal models [27], which could potentially offer another mechanism by which risks of EWDR associated with rapid HbA 1c reduction might be mitigated
Additionally, tirzepatide has properties of a dual agonist for both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors
[1] [2] These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon), among others
33 GLP-1 also reduces hepatic production of glucose by reducing the expression of key metabolic regulators of glycogenolysis
When saliva production decreases, plaque can accumulate more quickly, and the oral environment becomes more acidic
But both are employed to improve general health